IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today endorses the commitment and call to action by an initial group of global health actors, private sector partners and other stakeholders, to launch an unprecedented global and time-limited collaboration to accelerate the development, production and equitable global access to new COVID-19 essential health technologies.
The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today announces the publication of its first peer-reviewed scientific paper on biosimilar medicines development: The Path Towards a Tailored Clinical Biosimilar Development (Biodrugs).
The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today requests urgent action by all governments to designate all medicines as PRIORITY ESSENTIAL PRODUCTS, including all critical goods needed to manufacture them, so as to ensure that patients around the globe can continue to access the medicines they need during the COVID-19 pandemic.
- COVID-19: IGBA urgent recommendations to keep medicine supply chains flowing (27 March 2020)
- COVID-19: Urgent call to governments - Air freight must reopen for critical medicines and supplies for their manufacture (23 March 2020)
- COVID-19: Critical to keep the supply chain of essential medicines manufacturing operating at full capacity (18 March 2020)
- Hanan Sboul takes over the position of IGBA Chair (January 2020)
